Nicotine and the central nervous system: biobehavioral effects of cigarette smoking.
Level 5 - mechanism / opinion, no new human data
Narrative review describing biological mechanisms and expert recommendations without systematic search or primary empirical data.
PubMed 1353943 · doi:10.1016/0002-9343(92)90619-m
What was done
This paper reviewed the neuroregulatory and physiological mechanisms through which nicotine acts on the central nervous system to reinforce smoking behavior. It evaluated the pharmacokinetic differences between inhaled nicotine and slower-onset nicotine replacement vehicles, alongside considerations for smoking cessation strategies.
What was found
No quantitative data, sample sizes, or effect estimates were reported in the abstract. The narrative overview describes dose-dependent increases in plasma nicotine from smoking that alter dopamine bioavailability and raise levels of norepinephrine, epinephrine, arginine vasopressin, beta-endorphin, adrenocorticotropic hormone, and cortisol. The abstract states that inhaled delivery maximizes drug reinforcement due to immediate onset, whereas nicotine gum has a slower onset; it suggests cessation rates improve when nicotine replacement doses (such as 2 or 5 mg gum) are tailored to dependence severity and combined with behavioral modification.
Why it matters
The paper contextualizes the neurochemical mechanisms driving tobacco addiction and outlines the rationale for combining dose-tailored pharmacotherapy with behavioral support.
Limits
The abstract describes a narrative review with no systematic search criteria, quality appraisal, or quantitative pooling of data. No primary empirical data, sample sizes, effect sizes, or confidence intervals are provided.
Cited by
- supports Nicotine crossing the blood-brain barrier and binding to nicotinic acetylcholine receptors triggers the release of dopamine, norepinephrine, and beta-endorphin.